Stock Track | Zai Lab Soars 5.05% Intraday on Clinical Collaboration with Boehringer Ingelheim for Novel Cancer Therapy

Stock Track04-16

Zai Lab's stock surged 5.05% during intraday trading following the announcement of a significant clinical partnership.

The company has entered into a collaboration with Boehringer Ingelheim to develop an innovative dual DLL3-targeting combination therapy for extensive-stage small cell lung cancer. The partnership will evaluate Zai Lab's ADC drug, zocilurtatug pelitecan, in combination with Boehringer Ingelheim's T-cell engager, obrixtamig.

Investor sentiment was bolstered by recent positive Phase I clinical results for Zai Lab's drug candidate, which demonstrated potent and durable responses in previously treated patients, including those with brain metastases, alongside a favorable safety profile. This progress has enabled the program to advance into a global Phase III registrational study.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129093434?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 15:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129093434","market":"nz","top_or_hot":-1,"title":"Stock Track | Zai Lab Soars 5.05% Intraday on Clinical Collaboration with Boehringer Ingelheim for Novel Cancer Therapy","media":"Stock Track","content":"<p>Zai Lab's stock surged 5.05% during intraday trading following the announcement of a significant clinical partnership.</p><p>The company has entered into a collaboration with Boehringer Ingelheim to develop an innovative dual DLL3-targeting combination therapy for extensive-stage small cell lung cancer. The partnership will evaluate Zai Lab's ADC drug, zocilurtatug pelitecan, in combination with Boehringer Ingelheim's T-cell engager, obrixtamig.</p><p>Investor sentiment was bolstered by recent positive Phase I clinical results for Zai Lab's drug candidate, which demonstrated potent and durable responses in previously treated patients, including those with brain metastases, alongside a favorable safety profile. This progress has enabled the program to advance into a global Phase III registrational study.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Zai Lab Soars 5.05% Intraday on Clinical Collaboration with Boehringer Ingelheim for Novel Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Zai Lab Soars 5.05% Intraday on Clinical Collaboration with Boehringer Ingelheim for Novel Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-16 15:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zai Lab's stock surged 5.05% during intraday trading following the announcement of a significant clinical partnership.</p><p>The company has entered into a collaboration with Boehringer Ingelheim to develop an innovative dual DLL3-targeting combination therapy for extensive-stage small cell lung cancer. The partnership will evaluate Zai Lab's ADC drug, zocilurtatug pelitecan, in combination with Boehringer Ingelheim's T-cell engager, obrixtamig.</p><p>Investor sentiment was bolstered by recent positive Phase I clinical results for Zai Lab's drug candidate, which demonstrated potent and durable responses in previously treated patients, including those with brain metastases, alongside a favorable safety profile. This progress has enabled the program to advance into a global Phase III registrational study.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"","article_id":"1129093434","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129093434","pubTimestamp":1776323834,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Zai Lab's stock surged 5.05% during intraday trading following the announcement of a significant clinical partnership.The company has entered into a collaboration with Boehringer Ingelheim to develop...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09688":"再鼎医药"},"translate_title":"个股追踪|再鼎医药盘中大涨5.05%与勃林格殷格翰临床合作新型癌症疗法","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1},"content_text":"Zai Lab's stock surged 5.05% during intraday trading following the announcement of a significant clinical partnership.The company has entered into a collaboration with Boehringer Ingelheim to develop an innovative dual DLL3-targeting combination therapy for extensive-stage small cell lung cancer. The partnership will evaluate Zai Lab's ADC drug, zocilurtatug pelitecan, in combination with Boehringer Ingelheim's T-cell engager, obrixtamig.Investor sentiment was bolstered by recent positive Phase I clinical results for Zai Lab's drug candidate, which demonstrated potent and durable responses in previously treated patients, including those with brain metastases, alongside a favorable safety profile. This progress has enabled the program to advance into a global Phase III registrational study.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129093434","isCrawlerRequest":true}